Abstract
INTRODUCTION
Crohn's disease (CD) is a transmural chronic inflam matory disease that can affect any part of the alimentary tract, but which often involves the distal ileum.
Antitumor necrosis factorα (antiTNFα) mono clonal antibodies are generally used for inducing and maintaining remission and can be used alone or in combination with other drugs [1] . The most common drugs in this group, for CD, are infliximab (chimeric murine human IgG1 monoclonal antibody targeting TNFα), adalimumab (fully humanized IgG1 anti TNFα monoclonal antibody), and certolizumab pegol (a humanized monoclonal Fab′ fragment with a high binding affinity for TNF-α) [2, 3] . Although the majority of patients benefit from anti-TNF treatment, approximately onethird of patients treated with an induction dose of antiTNF do not improve clinically, termed primary nonresponse [3] . An additional significant population who initially respond to treatment eventually lose responsiveness, termed a secondary nonresponse.
Identifying patients who will fail treatment with antiTNF agents is of significant importance both from a clinical and economic perspective. AntiTNF drugs have been associated with an increased risk of opportunistic infections, melanoma, and lymphoma [46] . AntiTNF treatment is also very expensive, with 2013 annual per patient costs for adalimumab and infliximab at approximately $25000 and $24000 respectively [7, 8] . Factors associated with the success of antiTNF treatment include shorter disease duration, inflam matory (as opposed to fibrostenotic) disease phenotype, isolated colonic disease, young age, nonsmoking status, as well as a serum high Creactive protein that returns to normal after initiation of treatment [911] . Non response can be due to multiple factors such as an alternative non-TNF mediated pathway of inflammation, due to a differential role of TNF in certain stages of disease and/or due to the presence or development of antidrug antibodies. Additionally, individual differences in drug bioavailability and pharmacokinetics can be factors associated with nonresponse [9] . A possible conduit to predict response to antiTNF therapy could be through genetic testing. Several genes have been implicated in the pathogenesis of CD, including NOD2 and ATG16L1 [12, 13] . There is, however, limited data on the ability to predict anti TNF treatment response in CD based upon genetic data. Some genes have been investigated without success [14] . Our aim was to investigate genetic factors that might help define which CD patients are likely to benefit from anti-TNF therapy and permit efficient and cost-effective treatment. We hypothesized that specific single nucleotide polymorphism (SNP) genotypes are associated with antiTNF treatment response in patients with CD. We chose to examine a series of SNPs within genes that have been linked either with CD and/or with antiTNF treatment response in order to determine whether these could aid in predicting response to antiTNF treatment in CD patients.
MATERIALS AND METHODS
This study complies with the STROBE guidelines and the extension for genetic association studies [15] .
Patient recruitment and data collection
This is a prospective cohort study approved by the University of Louisville Institutional Review Board. All patients signed a written informed consent. Consecutive patients with a diagnosis of CD were identified from a large prospectively maintained genetic database, from a large University digestive disease practice, encompassing the period 1/1998 to 4/2016. Inclusion criteria were CD patients who had received antiTNF therapy, and whose medical records were available, with information about receipt of antiTNF therapy, its duration, efficacy, and cessation where applicable. Included patients received appropriate drug doses and had a followup of at least 12 mo following treat ment initiation [16, 17] . Patients were excluded if antiTNF treatment was stopped due to sideeffects, local and/ or systemic allergy, or if it was impossible to distinguish from the medical records whether the drug worked.
Additional data collected from the medical records included gender, race, socioeconomic status (patient's zip code of residence was used to obtain median household income based on United States census data from the American Community Survey 2014 5 year estimates) [18] , surgical history, and clinical state of the disease according to the Montreal classification for CD, including age at diagnosis, location, disease behavior, and the presence or absence of perianal disease [19] . The main outcome measure (following exposure to the drug) was response to therapy. Participants were grouped as everresponders if they had initial response to antiTNF treatment (even if this was later lost due to antibody formation) or nonresponders in accordance with the treating physician decision. The patient genotypes (see below) were assessed as the predictors of outcome. Possible confounders and effect modifiers included age, gender, race, and socioeconomic status disease, as well as disease characteristics (such as Montreal criteria).
DNA extraction
Peripheral blood was collected by venipuncture (after written informed consent) in EDTAvacutainers (BD, Franklin Lakes, NJ, United States) and stored at 4 ℃ until further use.
Genomic DNA was extracted from blood samples using the illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare, Pittsburgh, PA, United States) using the manufacturer's protocol [20] . Briefly, the blood was initially diluted with PBS buffer. Blood was then lysed: 1 μL of diluted blood was lysed with 1 μL of cell lysis solution (400 mmol/L KOH, 10 mmol/L EDTA, 100 mmol/L DTT), followed by the addition of 
SNP genotyping
SNPs selection: A PubMed literature search was conducted using the keywords "tumor necrosis factoralpha", "antiTNF", "infliximab", "adalimumab", "polymorphism", "Crohn's disease", "response", "biomarker" using Boolean operators (AND), (OR), (NOT). Results were narrowed down to original studies investigating SNPs including frequency of alleles and genotypes for different groups. We included SNPs that had demonstrated association with CD or anti TNF treatment, those that had biological relevance, and those that had an expected minor allele frequency ≥ 5%. Both new genetic associations and previously described efforts were investigated. SNPs were excluded if they had been extensively investigated and if there was no prognostic value for the combination of CD and antiTNF treatment response. As a result of this search, the following seven SNPs within 5 genes were selected for study and assessed in each patient's DNA sample: ATG16L1 (rs10210302, T300A rs2241880), Fas ligand (843 rs763110), IBD5 (rs2522057), FCGR 3A (rs396991), and TNF (308 rs1800629, 238 rs361525). SNP assessment was performed using TaqMan ® predesigned genotyping assays (Life Technologies ® , Carlsbad CA) [21] . The TaqMan included in this study. Following this, characteristics between everresponders and nonresponders in the study group were then compared [23] . HardyWeinberg equilibrium was determined for each SNP (Table 1) . Univariable logistic regression was modeled for the probability of antiTNF treatment failure for each covariate. Multivariable logistic re gression models were used for separate SNPs and covariates exhibiting a trend towards a significant difference (p < 0.15) [24] . Final models included OR and 95%CI. A pvalue of < 0.05 was considered statistically significant.
The statistical methods of this study were reviewed by Pan J and Rai SN. Table 1 shows a flow diagram of patient selection; 121 patients were selected for study. Of these, 21 (17.4%) patients were primary nonresponders to antiTNF treatment and 100 (82.6%) patients were ever responders to antiTNF treatment. A quarter of these initial everresponders (25/100) lost response at a later time and were termed secondary nonresponders. The patient population was predominantly Caucasian (92.6%), with a higher proportion of women (58.7%) ( Table 2) . With regards to clinical parameters, 90/121 (74.4%) patients were diagnosed between the ages of 17 and 40 years of age (Montreal A2). Most CD patients, 74/121 (61.2%), had combined ileocolonic disease (Montreal L3), whereas 15/121 (12.4%) had isolated ileal disease (Montreal L1), and 32/121 (26.4%) had only colonic disease (Montreal L2). Only 3/121 (2.5%) patients had upper GI (Montreal L4) involvement, all of whom were responders. Montreal L4 disease was analyzed separately from L13, due to the fact that, according to the Montreal classification, it is not mutually exclusive and can be added to any of the other locations when concomitant upper GI disease is present [19] . The population was fairly evenly distributed with respect to disease behavior with 36/121 (30%) patients having nonstricturing, nonpenetrating disease (Montreal B1), 45/121 (37%) patients having stricturing disease (Montreal B2), and 40/121 (33%) patients having penetrating disease (Montreal B3). In addition, 37 of 121 (31%) patients had perianal disease (Montreal p designation). Table 2 shows the clinical and demographic data of the participants, as well as these data for the nonresponder and ever responder groups. None of the clinical or demographic characteristics were significantly different between these 2 groups.
RESULTS

Patient demographics
Presence of bias
When comparing the characteristics of the patients who received antiTNF treatment and included in the study (n = 121) with those who did not receive anti TNF treatment (n = 152) in order to ascertain the were used. Six microliters of master mix was used for each assay (5. 
Statistical analysis
Descriptive and analytical statistics were performed using SAS version 9.4 statistical software [22] . Genotype frequencies, demographic, and disease characteristics were compared using a χ 2 test (or Fisher's exact test for 2 × 2 tables). Socioeconomic status was calculated according to the national percentile of the patient' s median household income divided into quartiles (025, 2650, 5175 and 76100) and compared using a χ 2 test. Comparison of continuous variables was performed using a twosample ttest or ANOVA. In order to explore for the presence of bias in the cohort, a group of contemporary subjects who did not receive antiTNF treatment were compared with patients We assessed 7 different SNPs associated with 5 different genes and observed less than 5% technical failure rate in all assays. Table 3 shows the SNPs tested as well as their genotype and allele distribution.
Comparison of genotypes between ever responders and nonresponders (Table 4) The vast majority of participants were Caucasian. Only 9 patients were African American, all of whom were everresponders. Analyzing the Caucasians separately as a sensitivity analysis achieved similar results for the grouped Fas ligand SNP (p = 0.029) and for the grouped 308 TNF gene SNP (p = 0.049). No significant difference was observed for the re maining SNPs studied: ATG16L1 (rs10210302, T300A rs2241880), IBD5 (rs2522057), FCGR 3A (rs396991), and TNF (238 rs361525).
Results of the univariable comparisons are shown in Table 5 . In univariable analyses, the Fas ligand SNP (rs763110) demonstrated a difference between ever responders and nonresponders with borderline sig nificance (p = 0.058) and significance when grouping TC and TT genotypes together (p = 0.020). The Logistic multivariable regression models were developed for the Fas ligand (rs763110) SNP, the TNF gene 308A/G (rs1800629) SNP, and their combination. The multivariable logistic regression models included genotype data for each of these two SNPs (with genotypes grouped as described above), the Montreal disease behavior classification, and the Montreal perianal disease classification ( Table 6) 
DISCUSSION
We identified two SNPs, Fas Ligand SNP (rs763110) and the TNF gene 308 (rs1800629), as being asso ciated with CD patient response to antiTNF treatment.
The Fas ligand SNP (rs763110) genotype fre quencies were significantly different between non responders and everresponders (p = 0.042). This association became more significant when grouping the TC and TT genotypes as compared to the CC genotype (p = 0.016). According to our multivariable analysis, the odds of a patient with a Fas ligand CC genotype being a nonresponder were fourfold higher as compared with a TC or TT genotype (p = 0.009, OR = 4.30, 95%CI: 1.45-12.80), when controlling for both Montreal disease behavior and perianal disease classification.
Abnormal regulation of apoptosis is one of the mecha nisms of CD pathogenesis. Apoptosis (programmed cell death) can be induced through both extrinsic and intrinsic pathways [25] . The extrinsic pathway is controlled through plasma membrane receptors belonging to the TNF receptor superfamily that include, among others, the Fas/Fas ligand which has been implicated in inflammatory bowel disease (IBD) [26, 27] . The SNP that we examined (rs763110) in the 843 position, which was located in a binding motif for the transcription factor CAAT/enhancerbinding protein β, has been implicated in carcinogenesis through the dysregulation of apoptosis [28] . Higher basal expression of Fas ligand has been significantly associated with the C allele compared with the T allele of this SNP [29] . The mechanism of action of anti-TNF drugs is complex; affecting many pathways, involving both soluble and membrane bound TNF [30] . Currently, antiTNF treatments have not been linked directly with Fas ligand; however, an interaction is possible either directly with the Fas ligand or indirectly by affecting the cells upon which the Fas ligand acts. Hlavaty et al [31] examined response to infliximab and the Fas ligand (rs763110) SNP and found the TT genotype to be correlated with nonresponse. The TNF gene SNP was also found to be asso ciated with response to antiTNF treatment. Two polymorphisms: 308 (rs1800629) and 238 (rs361525), both in the promotor region have previously had conflicting data reported with respect to response to antiTNF treatment in rheumatoid arthritis and in IBD [11, 3235] . The 308 (rs1800629) SNP has been shown previously to affect regulation of TNFα synthesis, with the minor allele (A) being a powerful transcriptional activator associated with increased TNFα production with the common allele (G) [36, 37] . Our study demonstrated a possible correlation with anti TNF treatment response with the 308 (rs1800629) SNP. Separately, 308 (rs1800629) when examined by itself demonstrated only a trend towards significance, but when combined with disease behavior and perianal disease, a significant correlation was demonstrated (p = 0.049, OR = 2.88, 95%CI: 1.01-8.22). The presence of the AA and GA genotypes (A being the minor allele) was correlated with nonresponse, implying a 2.88 higher odds of being a nonresponder to antiTNF treatment if the patient has an A allele. The fact that the A allele is observed fairly infrequently (19.6% in our study, and 9%16% in others [38] ) may explain the borderline statistical significance of this finding. additive effect compared to each SNP separately, most likely acting by different mechanisms. Considering that they are also found on different chromosomes (1 and 6), they are also in all probability inherited independently. The 238 TNF gene SNP (rs361525) did correlate with response to antiTNF treatment. This combination was found in 16 patients in our study (13%). The ATG16L1 gene has been well described in CD and has an important role in autophagy [39] . A SNP in this gene (rs2241880) has been linked to diminished autophagy, predisposing to CD [40] . Our study did not show an association with antiTNF treatment response for this SNP, nor for another SNP on this gene (rs10210302) that had shown promise as a predictor for response to adalimumab in Slovenian CD patients [41] . Another region, the 5q31 gene cluster (IBD5), has been described to confer CD risk in some popula tions [4244] . A SNP in this cluster (rs2522057) may be associated with response to infliximab in CD [45] . We were, however, unable to demonstrate such a correlation.
Antibodydependent cellmediated cytotoxicity is important in the mechanism of action of antiTNF drugs. It requires leukocyte receptors for the Fc portion of IgG. A polymorphism (rs396991) in the gene encoding FCGR 3A expressed on macrophages and natural killer cells was associated with the response to rituximab in follicular nonHodgkin's lymphomas [46] . This polymorphism has also been associated with the response to infliximab in CD [47] , but this was not able to be confirmed in our study.
Our study population included patients from a large university digestive practice. The patients included in the study and receiving antiTNF drugs were younger than the excluded nonantiTNF treated patients but were comparable with respect to race, gender, and socioeconomic status. Their younger age can be explained by the fact that younger patients tend to have a more severe disease [1] and would probably require antiTNF drugs more frequently. Since patients were comparable in other aspects, we believe there was no selection bias. All CD patients were followed by gastroenterologists and surgeons, and as such, had a higher incidence of complicated CD. This may be a source of potential bias. This may also explain why we did not observe a difference with respect to likelihood of antiTNF treatment response and disease behavior which has been observed in prior studies [9] . The clinical allocation into groups was performed by experienced clinicians (Galandiuk S, Dryden GW), who deal with this population on a daily basis. The assessment was made on the basis of the patient history, physical exam, patient followup, labwork and endoscopy/pathology when clinically indicated. This study assessed nonresponse (no improvement whatsoever) vs everresponse. Since this was not a formal clinical trial and since only a quarter of patients had colonic disease, colonoscopy was not performed at defined intervals, but at the discretion of the treating physician. This could be a source of bias, but we believe that clinical assessments based on the above criteria are valid.
In summary, identification of patients whose anti-TNF treatment will fail is important, both from a clinical and from an economic perspective. We have identified two functional SNPs, Fas ligand (rs763110) and the TNF gene 308 (rs1800629), associated with non response to antiTNF treatment. Genotyping these SNPs from DNA obtained from peripheral blood may help define which CD patients are likely to benefit from anti-TNF therapy and permit efficient and cost-effective treatment by avoiding expensive therapy that is likely to fail and permitting selection of other treatments 
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